These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 8097546)
1. Amisulpride evaluation by radioreceptor assay comparison with HPLC procedure after single administration in the rabbit. Mokrim R; Brunet C; Cazin M; Gressier B; Luyckx M; Dine T; Robert H; Cazin JC Methods Find Exp Clin Pharmacol; 1993; 15(1):41-7. PubMed ID: 8097546 [TBL] [Abstract][Full Text] [Related]
2. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185 [TBL] [Abstract][Full Text] [Related]
3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of amisulpride in rat plasma by HPLC-MS/MS. Noh K; Jang YJ; Kwon KI; Kim E; Jeong TC; Yun HY; Kang W Arch Pharm Res; 2015 Jan; 38(1):63-7. PubMed ID: 24619919 [TBL] [Abstract][Full Text] [Related]
5. Disposition of enantiomers of sultopride in a human, rats and rabbits. Kamizono A; Inotsume N; Fukushima S; Nakano M Biol Pharm Bull; 1993 Nov; 16(11):1121-3. PubMed ID: 7906175 [TBL] [Abstract][Full Text] [Related]
6. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793 [TBL] [Abstract][Full Text] [Related]
7. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321 [TBL] [Abstract][Full Text] [Related]
8. Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. Gschwend MH; Arnold P; Ring J; Martin W J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):132-9. PubMed ID: 16386474 [TBL] [Abstract][Full Text] [Related]
9. Competitive MS binding assays for dopamine D2 receptors employing spiperone as a native marker. Niessen KV; Höfner G; Wanner KT Chembiochem; 2005 Oct; 6(10):1769-75. PubMed ID: 16149041 [TBL] [Abstract][Full Text] [Related]
10. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo]. Abaimov DA; Zimin IA; Kovalev GI Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481 [TBL] [Abstract][Full Text] [Related]
11. Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system. Bock N; Moll GH; Wicker M; Pilz J; Rüther E; Banaschewski T; Huether G; Rothenberger A Pharmacopsychiatry; 2004 Jul; 37(4):163-7. PubMed ID: 15467972 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the effect of substituted benzamides in radioreceptor binding assays with their effects on brain dopaminergic systems in vivo. Lin CW; Wilk S Adv Biochem Psychopharmacol; 1982; 35():51-60. PubMed ID: 6183929 [No Abstract] [Full Text] [Related]
14. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Cudennec A; Fage D; Bénavidès J; Scatton B Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323 [TBL] [Abstract][Full Text] [Related]
15. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840 [TBL] [Abstract][Full Text] [Related]
16. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Bergemann N; Kopitz J; Kress KR; Frick A Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484 [TBL] [Abstract][Full Text] [Related]
17. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Rosenzweig P; Canal M; Patat A; Bergougnan L; Zieleniuk I; Bianchetti G Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702 [TBL] [Abstract][Full Text] [Related]
18. Monitoring of serum bioactivity levels of perazine and its metabolites by radioreceptor assay. Rao ML Pharmacopsychiatry; 1989 May; 22(3):104-7. PubMed ID: 2568642 [TBL] [Abstract][Full Text] [Related]
19. Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat. Hilakivi I; Rinne J; Marjamäki P Pol J Pharmacol; 1999; 51(4):311-6. PubMed ID: 10540962 [TBL] [Abstract][Full Text] [Related]
20. Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma. Moulin A; Truffer D; Rauch-Desanti C; Istin M; Grognet JM; Dufour A Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():507-12. PubMed ID: 1820931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]